Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSenseâ„¢ Adaptive deep brain stimulation (aDBS) and BrainSenseâ„¢
Pharm Exec · 2d
FDA Approves Medtronic’s BrainSense Adaptive Deep Brain Stimulation for Parkinson Disease
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real-time brain activity to improve Parkinson disease symptom control without manual adjustments.
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results